Evidence map›Paper›PMID 41291024›Full record

ArticleScientific reports2025

Enhancing antiretroviral delivery to secondary lymph nodes by targeting CD169 + macrophages with HIV-mimicking nanoparticles.

Josiane Fofana, Sonia Zahara, Tiffany Chan, Han Zang, Björn M Reinhard, Suryaram Gummuluru

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Josiane FofanaDepartment of Virology, Immunology and Microbiology, Boston University Chobanian & Avedisian School of Medicine, 650 Albany St., X343C, Boston, MA, 02118, USA.
Sonia ZaharaDepartment of Chemistry and the Photonics Center, Boston University, Boston, MA, 02215, USA.
Tiffany ChanDepartment of Biology, Boston University, Boston, MA, 02215, USA.
Han ZangDepartment of Chemistry and the Photonics Center, Boston University, Boston, MA, 02215, USA.
Björn M ReinhardDepartment of Chemistry and the Photonics Center, Boston University, Boston, MA, 02215, USA.
Suryaram GummuluruDepartment of Virology, Immunology and Microbiology, Boston University Chobanian & Avedisian School of Medicine, 650 Albany St., X343C, Boston, MA, 02118, USA. rgummulu@bu.edu.

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI LARRY K BROWN · 1998 to 2026
$51.7M
RESEARCH TRAINING IN IMMUNOLOGYT32AI007309 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GUMMULURU, SURYARAM · 1988 to 2024
$7.4M
Improved Nanoparticle Targeting of Tissue Myeloid Cells for HIV-1 Long-acting Pre-exposure ProphylaxisR01AI175068 · NIAID · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI Zandrea Ambrose, SURYARAM GUMMULURU · 2023 to 2026
$2.9M
GM3 Nanoparticles for Sustained Delivery of Anti-Retrovirals to Lymphatic TissuesR01AI132111 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GUMMULURU, SURYARAM, REINHARD, BJOERN MARKUS · 2018 to 2022
$2.7M
High Sensitivity In Vivo Imaging System with Integrated Micro-Computed Tomography for Animal Phenotyping CoreS10OD030501 · OD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SETA, FRANCESCA · 2022 to 2022
$600k
Dual antiretroviral loaded nanoparticles for long-acting suppressive HIV therapyF31AI172625 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FOFANA, JOSIANE · 2022 to 2024
$70k
National Institute of Allergy and Infectious Diseases F31AI172625National Institute of Allergy and Infectious Diseases R01AI132111NIAID NIH HHS F31 AI172625NIAID NIH HHS P30 AI042853NIAID NIH HHS R01 AI132111NIAID NIH HHS R01 AI175068NIAID NIH HHS T32 AI007309NIH HHS S10 OD030501
6 · The paper itself

Abstract

Despite significant progress in combinatorial antiretroviral therapy, people living with HIV remain susceptible to co-morbidities and increased risks of mortality. Chronic inflammation and immune activation are correlated with viral persistence in reservoir sites such as secondary lymph nodes and are postulated to be a driver of exaggerated risk of HIV-associated co-morbidities. Previous studies have revealed that low and heterogeneous penetration of antiretrovirals (ARVs) in lymph nodes can contribute to viral persistence. In addition, sub-optimal adherence to daily oral ARVs can lead to the development of antiviral resistance and viral rebound from these sanctuary sites. To overcome these deficiencies, we developed membrane-wrapped poly-lactic acid nanoparticles expressing the ganglioside, GM3 (GM3-NPs) and incorporating dual ARVs, Rilpivirine and Cabotegravir (CAB), for targeted delivery to lymph nodes. We have previously shown that GM3-CD169 mediated uptake of NPs results in their prolonged retention in CD169

Indexed as

Anti-HIV AgentsAnti-Retroviral AgentsHIV InfectionsLymph NodesMacrophagesNanoparticlesSialic Acid Binding Ig-like Lectin 1AnimalsDrug Delivery SystemsG(M3) GangliosideHIV-1HumansMicePyridonesRilpivirineAnti-HIV AgentsAnti-Retroviral AgentsG(M3) GangliosidePyridonesRilpivirineSialic Acid Binding Ig-like Lectin 1

Identifiers

PMID41291024
PMCPMC12748623

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.